S
Steven P. Marso
Researcher at Research Medical Center
Publications - 201
Citations - 24616
Steven P. Marso is an academic researcher from Research Medical Center. The author has contributed to research in topics: Percutaneous coronary intervention & Conventional PCI. The author has an hindex of 53, co-authored 197 publications receiving 20602 citations. Previous affiliations of Steven P. Marso include Cleveland Clinic & Hospital Corporation of America.
Papers
More filters
Journal ArticleDOI
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso,Gilbert H. Daniels,Kirstine Brown-Frandsen,Peter Lommer Kristensen,Johannes F.E. Mann,Michael A. Nauck,Steven E. Nissen,Stuart J. Pocock,Neil R Poulter,Lasse Steen Ravn,William M. Steinberg,Mette Stockner,Bernard Zinman,Richard M. Bergenstal,John B. Buse +14 more
TL;DR: In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, orNonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.
Journal ArticleDOI
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P. Marso,Stephen C. Bain,A. Consoli,Freddy G. Eliaschewitz,Esteban Jódar,Lawrence A. Leiter,Ildiko Lingvay,Julio Rosenstock,Jochen Seufert,Mark Warren,Vincent Woo,O Hansen,Anders G. Holst,Jonas Pettersson,Tina Vilsbøll +14 more
TL;DR: In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, orNonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semag lutide.
Journal ArticleDOI
A Prospective Natural-History Study of Coronary Atherosclerosis
Gregg W. Stone,Akiko Maehara,Alexandra J. Lansky,Bernard De Bruyne,Ecaterina Cristea,Gary S. Mintz,Roxana Mehran,John A. McPherson,Naim Farhat,Steven P. Marso,Helen Parise,Barry Templin,Roseann White,Zhen Zhang,Patrick W. Serruys +14 more
TL;DR: In patients who presented with an acute coronary syndrome and underwent percutaneous coronary intervention, major adverse cardiovascular events occurring during follow-up were equally attributable to recurrence at the site of culprit lesions and to nonculprit lesions.
Journal ArticleDOI
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R. Holman,M. Angelyn Bethel,Robert J. Mentz,Vivian P. Thompson,Yuliya Lokhnygina,John B. Buse,Juliana C.N. Chan,Jasmine Choi,Stephanie M. Gustavson,Nayyar Iqbal,Aldo P. Maggioni,Steven P. Marso,Peter Öhman,Neha J. Pagidipati,Neil Poulter,Ambady Ramachandran,Bernard Zinman,Adrian F. Hernandez +17 more
TL;DR: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo.
Journal ArticleDOI
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F.E. Mann,David D. Ørsted,Kirstine Brown-Frandsen,Steven P. Marso,Neil Poulter,Søren Rasmussen,Karen Tornøe,Bernard Zinman,John B. Buse +8 more
TL;DR: This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo.